Skip to main content
OpenTrials
Completed

NCT Number: NCT01438359

A Drug-Drug Interaction Study of Furosemide and PA21

The purpose of this study is to determine if Furosemide is affected by PA21.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy

Age range

20 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

ACRI - Phase 1

Anaheim, California, 92801, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy volunteers
  • Written informed consent

Exclusion criteria

  • No significant medical conditions
  • Pregnancy

Treatment and study plan

PA21 and Furosemide with food

Drug

The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Furosemide will be 40 mg/day

No PA21; Furosemide with food

Drug

The maximum dosage of Furosemide will be 40 mg/day

PA21 with food and Furosemide 2hrs later

Drug

The maximum dose of PA21 will be 15 g/day. The maximum dose of Furosemide will be 40 mg/day

Primary outcomes

  1. Effect of PA21 on Furosemide

    Time frame: PK assessment on Day 0, 11, and 22: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48 hrs post furosemide dose

    To assess the effect, if any, of PA21 on Furosemide exposure(AUC0-24; AUC0-infinity; Cmax; Tmax and t1/2).

Sponsors and collaborators

Lead sponsor

Vifor Pharma

Industry

Registry information

Official study title

A Single-centre, Open-label, Three-period Study of the Pharmacokinetic Effect of PA21 on Furosemide in Healthy Male and Female Adults

Important dates

Study start
2011
Primary completion
2011
Study completion
2011
First posted
Sep 22, 2011
Registry last updated
Sep 30, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.